European Archives - Page 1005 of 1051 - European Medical Journal

Continue
EMJ
4 Mins
3 Mar 2015

When Does Bladder Cancer Get Its Turn?

The past decade, and particularly the past five years have been an exciting time in the management of prostate cancer. After what seemed like an eternity…
EMJ
3 Mins
3 Mar 2015

New Horizons in Prostate Cancer

Research and development in the 21st century is a rapidly changing landscape. Advances in technology have been the driving force to further advances in…
3 Mar 2015

Hypertension Care: It’s Time to Act

The satellite symposium was held in two separate sessions – the first a traditional symposium format, and the second as an interactive panel discussion in..
March 2015

EMJ Cardiology 3 [Suppl 1] 2015

The satelite symposium was held in two separate sessions – the first a traditional symposium format, and the second as an interactive panel discussion in which the faculty answered questions from the delegates. 
EMJ
2 Mar 2015

Antibiotic and Diuretic Can Form Dangerous Drug Duo in Elderly

SUDDEN death in older patients is twice as likely through the combination of the antibiotic trimethoprim-sulfamethoxazole and the diuretic spironolactone…
EMJ
2 Mar 2015

Personalised Medicine Methods Bolster Prostate Cancer Screening

OPTIMISATION of the prostate-specific antigen (PSA) test has been earmarked through the utilisation of methods from personalised medicine…
EMJ
3 Mins
27 Feb 2015

Big Ben, Covent Garden, and the Thames: Lessons Learned from a Visit to London—Collaboration Improves Outcomes

This past week I have had the honour and pleasure of introducing my book Women and Cardiovascular Disease in London. During the book-signing event, I was…
EMJ
27 Feb 2015

Gilead Announces SVR12 Rates from Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

Seattle, February 26, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from a Phase 3 study, ION-4, evaluating the once-daily…
EMJ
27 Feb 2015

Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF)

Seattle, February 26, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48week results from two Phase 3 studies (Studies 104 and 111)…
EMJ
25 Feb 2015

Living with a Rare Cancer

Lugano, 25 February 2015 – Within the “umbrella” of rare diseases, rare cancer patients confront particular problems. Most rare diseases have an…